(NYSE:STUB), PHILADELPHIA, Dec. 23, 2025 (GLOBE NEWSWIRE) — National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against StubHub Holdings, Inc. (NYSE: STUB) (“StubHub” or the “Company”) on behalf of investors who purchased or otherwise acquired StubHub securities during the period of September 14, 2025 through November 24, […]

CLASS ACTION NOTICE: Berger Montague Advises StubHub Holdings, Inc. (NYSE: STUB) Investors to Inquire About a Securities Fraud Class Action GlobeNewswire December 23, 2025 PHILADELPHIA, Dec. 23, 2025 (GLOBE NEWSWIRE) — National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against StubHub Holdings, Inc. (NYSE: STUB) (“StubHub” or

(NYSE MKT:SYNX), Netanya, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, recently announced that it received multiple purchase orders totaling over $1.3 million from leading defense organizations in Israel. These recent orders include: A $100,000 order from

(OTCQB:INNMF),(OTC US:INNMF),(AUST:ATX.AX), Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company's CMO Dr Jason Lickliter will present a poster at the forthcoming ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026, in San Francisco. The poster, titled Narmafotinib (AMP945) in

(NASDAQ:AMIX), Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment. As part of the segment, Brad Hauser, CEO of Autonomix,

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium GlobeNewswire December 23, 2025 Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company's CMO Dr Jason Lickliter will present a poster at the forthcoming ASCO Gastrointestinal Cancers Symposium, being held

Silynxcom Announces Over $1.3 Million in Purchase Orders from Israeli Defense Forces and Tactical Units in Recent Months GlobeNewswire December 23, 2025 Netanya, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, recently announced that it received multiple

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment GlobeNewswire December 23, 2025 Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments,

Miami, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) — An analysis of visa approval decisions by governments on 726,824 visa applications submitted between October 2024 and October 2025 reveals a consistent global trend: men are 62% more likely to have their visa application rejected than women. The dataset includes only completed government decisions; applications that were

Men are 62% more likely to have their travel visa rejected, iVisa's latest data reveals New analysis from the global travel platform iVisa reveals that men face significantly higher visa rejection rates than women, especially among younger male travelers. GlobeNewswire December 23, 2025 Miami, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) — An analysis of visa